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Abstract 
Dextromethorphan pharmacokinetics is markedly influenced by CYP2D6 enzyme 
polymorphisms. The aim of this study was to quantify the effect of the CYP2D6*1, *2 and 
*41 variants on dextromethorphan metabolism in vivo and to identify other sources of 
pharmacokinetic variability. Plasma and urine concentrations of dextromethorphan and 
dextrorphan were evaluated from 36 healthy Caucasian males. These volunteers participated 
in three clinical studies and received a single oral dose of 30 mg dextromethorphan-HBr. Data 
were modelled simultaneously using the population pharmacokinetic NONMEM software. A 
five-compartment model adequately described the data. Activities of the alleles assessed 
differed significantly. The clearance attributable to an individual CYP2D6*1 copy was 2.5-
fold higher compared to CYP2D6*2 (5010 vs 2020 L/h) while the metabolic activity for 
CYP2D6*41 was very low (85 L/h). Urinary pH was confirmed as a significant covariate for 
dextromethorphan renal clearance. These results refine genotype-based prediction of 
pharmacokinetics for dextromethorphan and presumably other CYP2D6 substrates. 
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Introduction 
Dextromethorphan (DM) is an antitussive drug with  rapid absorption from the 
gastrointestinal tract (ka= 2.6 +/- 0.9 h-1) after oral administration and a large central volume 
of distribution 961 L ranging from 585 to 1292 litres.(1) DM undergoes rapid and extensive 
first-pass metabolism mainly by CYP2D6 with an oral bioavailability ranging from 1% to 2% 
and about 80% in extensive and poor CYP2D6 metabolizer subjects, respectively(2) Its 
intrinsic hepatic clearance was about 22L/h and 4737 L/h in respective CYP2D6 metabolizer 
groupss,.(2) In another study a value of 1280 ± 483 L/h for its apparent clearance has been 
reported for CYP2D6 extensive metabolizers.(3) Primary metabolic steps include formation 
of dextrorphan (DO) mainly by CYP2D6 and of 3-methoxymorphinan by CYP3A enzymes. 
Both are further metabolized to 3-hydroxymorphinan by CYP3A4 and CYP2D6, 
respectively.(4, 5) The dominating metabolic pathway in the majority of the population is the 
conversion of DM to DO by CYP2D6, contributing to more than 80% to the formation of 
DO.(1, 6) The selectivity of DO formation via CYP2D6, in addition to its favourable safety 
and availability, has made DM a probe of choice for CYP2D6 phenotyping.(7) 
 
CYP2D6 is a highly polymorphic gene with more than 100 known allelic variants (March 15, 
2010; http://www.cypalleles.ki.se/cyp2d6.htm). Because the overall disposition of DM is 
highly dependent on CYP2D6 activity, these polymorphisms are the main source for the wide 
interindividual variation in its plasma levels and response.(8, 9) For other CYP2D6 substrates 
such as antidepressants and antipsychotic drugs such variability can lead to failure of 
treatment in carriers of alleles encoding very high CYP2D6 activity or may expose 
individuals carrying alleles conferring no or low activity to a high risk of toxicity.(10, 11) 
Conversely, for some opioids such as dihydrocodeine, codeine and tramadol, where a highly 
active metabolite is formed by CYP2D6, therapeutic failure may be associated with low 
activity genotypes and toxicity with genotypes resulting in high enzymatic activity.(12, 13) 
 
As a prerequisite to personalize therapy with CYP2D6 substrates, different proposals have 
been made to establish simple useful systems for the prediction of CYP2D6 phenotype based 
on CYP2D6 genotype.(14) Such predictions suffer from potential pitfalls depending on the 
correctness of underlying assumptions. The classical procedure divided populations based on 
the urinary metabolic ratio of DO over DM and an arbitrary “cut-off” value, i.e. antimode, 
into poor and extensive metabolizers.(15) While subjects with two non-functional alleles 
represent the poor metabolizer group, it is difficult to precisely predict the phenotype of 
individuals carrying combinations of functional and reduced function alleles. Furthermore, 
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wide variability in CYP2D6 activity is not only observed between subjects with different 
functional genotypes, but is also rather the rule than the exception among subjects within a 
genotype group.(16) Attempts to better classify especially those subjects carrying gene 
duplications and reduced function alleles, ultra-rapid and intermediate metabolizers subgroups 
have been introduced creating a polymodal population distribution.(17) 
 
Another system called semi-quantitative scoring system defining categories for CYP2D6 
alleles has been developed(18) which assigns scores to each allele (1 for fully functional 
alleles, 0.5 for reduced activity functional alleles, and zero for non-functional alleles) and uses 
these ‘gene doses’ as an indicator for phenotype. Another recent scoring system, the so-called 
activity score system, also assigns values to individual CYP2D6 alleles and utilizes their sum 
as a surrogate to predict phenotype.(8) Because the model did not improve when assigning 
values of 0.25 and 0.75 to alleles perceived to confer slight and substantial reduction in 
activity, the simplest model using values of 1 for fully functional, 0.5 for all reduced activity, 
and 0 for non-functional alleles, respectively, was chosen. In an effort to better describe the 
alleles carrying functional gene duplications such as CYP2D6*1xN or *2xN, the value of the 
allele was doubled, i.e. a value of 2 was assigned to CYP2D6*1xN. Although these 
classification systems have improved phenotype prediction, considerable variability within 
score groups persists.  
 
By definition, these scoring systems are valid for non-functional alleles such as CYP2D6*3 
and*4, but the simplifying assumption that fully functional alleles such as CYP2D6*1 and *2 
have identical activity enzymes can be challenged, as well as the allocation of a value of 0.5 
to any low activity allele. Indeed, several mechanisms including differences in splicing and 
other reasons for different expression levels, enzyme stability, and/or substrate specific 
enzyme kinetics may cause net differences for in vivo substrate turnover between individual 
functional CYP2D6 variants.  
 
Thus, there is a need to precisely quantify the in vivo activity associated with CYP2D6 allelic 
variants and genotypes to better predict phenotype from genotype data. Such information will 
ultimately be useful for clinical decision making in respect to drug selection and dose 
adjustment. In the present study we assessed the activity of individual CYP2D6 alleles with 
regard to the clearance of DM to DO, using a population pharmacokinetic approach.  
 
Results 
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A total number of 537 plasma samples and 136 urine samples from 36 healthy Caucasian men 
obtained after oral administration of a 30 mg DM-HBr dose were analysed for DM and DO 
concentrations in this study. Demographic and CYP2D6 genetic characteristics of these 
volunteers are given in Table 1 and 2, respectively.  
 
As expected, we observed large interindividual differences in the time-concentration profiles 
within the data set, with the highest variability for DM. DM initial plasma concentrations 
decreased rapidly in many, but not all, individuals (within the first 5 hours after dosing) 
reflecting the known variability in drug clearance. DO plasma concentrations appeared in 
many individuals earlier than the parent drug, supporting the importance of first-pass 
metabolism. 
 
Modelling all data with the basic structure 4-compartment model (see Methods section) was 
not sufficient to describe the data, with misspecifications especially for parent concentrations 
in plasma. Addition of a peripheral compartment for DM was associated with a significant 
drop in the objective function value (Δ= -114). Based on individual and population 
predictions, this model was still unable to account for the early appearance of DO in plasma. 
Therefore, other models (19, 20) that take the first pass metabolism into account were tested. 
These models were stepwise simplified or extended for modelling the available data. A 
hypothetical metabolism compartment was added assumed to be in rapid equilibrium with the 
central compartment of the parent drug, with all metabolic steps taking place in this 
compartment. After administration of the drug, it was assumed that the drug goes from the 
absorption site to the metabolism compartment before reaching the plasma (for specifications, 
see appendix A). This model was associated with a profound drop in the objective function 
value (Δ= -324). Inclusion of a lag-time parameter led also to further significant drop in the 
objective function (Δ= - 45).  
 
With respect to identification of covariates, as expected CYP2D6 genotype had a major 
impact on the metabolic clearance (Δ= - 532). About 55% of the interindividual variability 
(CV %) in DM metabolic clearance, CL23, was explained by addition of CYP2D6 genotype 
as a covariate. Inclusion of urine pH values as a covariate on renal clearance of DM also 
resulted in a significant drop in the objective function value (Δ= -105). The best form of this 
relationship was that included in the final model and is described by the following empirical 
equation: 
θPV = θTV ·(5.7/UpH)θs 
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where θPV is the individual value of renal clearance, θTV is the population value of renal 
clearance, the value 5.7 represent a published mean of urine pH in humans(21), UpH is the 
measured individual urine pH at each collection period, and θs is the shape parameter which 
explains the change in renal clearance in terms of change in urine pH. Using the non-ionized 
fraction of DM calculated according the Henderson-Hasselbalch equation as a covariate was 
inferior to this empirical equation. Including an effect of urine pH on renal clearance of DO 
did neither improve model fitting nor led to a decrease in the OFV. The model also identified 
age as important covariate. Age contributed to interindividual variability in the apparent 
volume of distribution of DO (Δ= -21.9) and the clearance of DO to other species, CL30, (Δ= -
5.8). This covariate was modelled according to the relationship: 
θPV = θTV · EXP (θAGE · (AGE – 27)) 
where θPV is the population value of the model parameter, θTV is the typical value in an 
individual with age of 27 years old (the median age in this study). θAGE is the fractional 
change in θPV per year different from 27 years of age. None of other apparent volumes of 
distribution, clearance, or inter-compartmental clearance parameters has been found to be 
influenced by age in this study. Neither body weight nor height was found to significantly 
contribute to model disposition parameters. Plasma data were best fitted if combined additive 
and proportional error terms were used, while urine data were best fitted with proportional 
error terms. The blueprint of the final model is shown in Figure 1.  
 
Final pharmacokinetic parameter estimates with 95% confidence intervals are shown in Table 
3. The apparent metabolic clearance (CL23) estimate ranged from 10 to 10030 L/h in this 
population. The fraction of the clearance attributable to a CYP2D6*1 copy was on average 
2.5-fold greater than that for CYP2D6*2. CYP2D6*41 related clearance was lowest: the point 
estimates per copy were 5010 L/h, 2020 L/h and 85 L/h for CYP2D6*1, *2 and *41, 
respectively.  
 
Diagnostic plots of the final model are given in Figure 2, indicating model adequacy. The 5th, 
50th and 95th percentiles from simulated data, based on the final model estimates, are shown in 
Figure 3. Simulated time courses of plasma concentrations and cumulative amounts excreted 
in urine for subjects who are homozygous for a given allele, i.e. CYP2D6*1/*1, *2/*2, etc, are 
given in figure 4. The expected values of standard CYP2D6 phenotypic metrics, i.e. metabolic 
ratios of DM over DO at 3h in plasma and 0-8h in urine, were 0.12 and 0.015 for CYP2D6*1/*1, 
0.28 and 0.04 for CYP2D6*2/*2, 5.0 and 0.079 for CYP2D6*41/*41, and 90.9 and 14.3 for 
CYP2D6*4/*4 carriers (simulated for a 27-years old male having a urine pH of 5.7).  
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Discussion 
The main objective of this study was to quantify the metabolic activity attributable to frequent 
individual CYP2D6 alleles using DM as a probe drug. The mean CYP2D6 mediated clearance 
CLCYP2D6 is estimated as 15030 L/h in subjects genotyped as CYP2D6 *1/*1x2, whereas it is 
170 L/h in subjects who carry two CYP2D6*41 alleles, and zero for subjects with genotypes 
comprising two non-functional alleles. The results suggest that quantitative differences in DM 
based phenotyping metrics between CYP2D6 genotypes are similar to the differences in 
enzyme activity, despite additional processes with impact on DM pharmacokinetics (see 
Table 3).  
 
Based on the final model estimates, the activity for the CYP2D6*1 allele with respect to 
formation of DO in vivo is about 2.5-fold higher compared to that seen for the CYP2D6*2 
allele. The CYP2D6.2 protein differs from the CYP2D6.1 protein in two amino acids (R296C 
and S486T) (http://www.cypalleles.ki.se/cyp2d6.htm), while there is no evidence that the 
CYP2D6*2 allele differs from the *1 allele with respect to expression levels. Key substrate 
binding sites of CYP2D6 include D301, F120, F483 and F481.(22) However, both positions 
296 and 486 are supposed to be part of the substrate recognition site regions(23), and 
especially replacement of the large positively charged arginine by cysteine close to position 
301 may well modify substrate binding but not profoundly change catalytic properties. 
Indeed, early reports by Sachse et al(17) showed that presence of the CYP2D6*2 allele was 
related to a slightly reduced enzyme activity as determined by urinary DM and/or 
debrisoquine phenotyping metrics. Both DM and pinoline intrinsic clearance for the 
respective O-demethylation in enzyme variants purified after expression using a baculovirus-
mediated system were only a fifth for CYP2D6.2 compared to CYP2D6.1.(24, 25) 
Differences were smaller but in the same direction for other reactions: DM N-demethylation, 
0.77-fold; codeine O-demethylation, 0.35-fold; and fluoxetine N-demethylation, 0.26-
fold.(24) Intrinsic clearance for CYP2D6.2 expressed in Saccharomyces cerevisiae compared 
to CYP2D6.1 was also about 0.5-fold lower for several progesterone hydroxylation pathways 
and 0.23-fold lower for dopamine formation from D-tyramine.(26) The respective activity 
ratio of CYP2D6.2 over CYP2D6.1 expressed in yeast was 0.44-fold for DM O-
demethylation and 0.74-fold lower for bufurolol 1’-hydroxylation, while there were no 
differences with regard to metabolism of debrisoquine or metoprolol.(27) In a COS-7 
expression system, CYP2D6.2 reached 0.71-fold and 0.72-fold activity relative to CYP2D6.1 
for DM O-demethylation and bufuralol hydroxylation.(28) In summary, on an average 
CYP2D6.2 is approximately half active than CYP2D6.1. Whether the reported differences in 
 8
this ratio between substrates in the in vitro assays are real or rather reflect the notorious 
problems in reproducibility of in vitro enzyme kinetic parameters(29) remains to be assessed 
in detail by clinical studies. Indeed, differences in urinary DM/DO metabolic ratios in a 
Gabonese population(30) showed the same difference between CYP2D6*1 and *2 carriers as 
observed here. 
 
Furthermore, this study shows that the metabolic clearance of DM conveyed by CYP2D6*41 
is markedly less than that of CYP2D6*1. It is well-known that the activity for CYP2D6*41 is 
lower when compared to CYP2D6*1 and *2. CYP2D6*41 codes for the lower activity 
CYP2D6.2 protein and in addition has a lower level of expression, as shown by 2- to 5-fold 
lower levels of CYP2D6 mRNA containing exon 6, apoprotein and enzyme activity in 
mechanistic studies.(31) When comparing to individuals with only one functional *1 allele, 
there was a 0.27-fold lower mean enzyme activity in individuals with one functional *41 
allele as quantified by the sparteine metabolic ratio (data taken from graph) (32). This is the 
first quantitative estimate for activity attributable to CYP2D6*41 in vivo based on DM O-
demethylation. The extent of the difference (0.017-fold) is approximately one order of 
magnitude higher than expected from previous information and needs to be confirmed in 
larger groups with this genotype. 
 
The finding that the CYP2D6*1 allele is associated with an about 2.5-fold higher activity with 
dextromethorphan compared to CYP2D6*2 would suggest that different activity values need 
to be assigned to these alleles in scoring systems. Both the activity score(8) and semi-
quantitative scoring(18) systems assumed similar activity for the CYP2D6*1 and *2 alleles. 
To reflect reduced activity, these systems(8, 18) assigned a value of 0.5 to the CYP2D6*41 
allele. Based on the results presented here, clearance for CYP2D6*41 is approximately 60-
fold reduced in comparison to CYP2D6*1. Consequently scoring values of 1, 0.4 and 0.017 
should be assigned to CYP2D6*1, *2 and *41, respectively to more accurately reflect their 
activity. Using the respective final parameter estimates, DM pharmacokinetics for various 
genotypes were simulated (Figure 4). Similar genotype specific predictions can be made for 
other CYP2D6 substrates. Such predictions, however, may need to be modified, since 
previous studies demonstrated that protein specific activity of cytochrome P450 enzymes 
including CYP2D6 is in part substrate dependent.(11, 33, 34) 
 
The final pharmacokinetic model describes the pharmacokinetic profiles of DM and its major 
metabolite adequately. In this model, inclusion of the hypothetical metabolism compartment 
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was able to explain the appearance of DO in plasma before DM. The presented model shares 
some features with previously reported models that have been successfully applied to describe 
first-pass metabolism.(1, 20) The specific features in our model are that, (i) activity of active 
alleles of CYP2D6 were estimated separately, (ii) urinary data of both parent and metabolite 
were included in the model and simultaneously evaluated with plasma data; (iii) the impact of 
urine pH on DM clearance was quantified; (iv) it can be extended to estimate the activity of 
other additional alleles such as *9, *10, and *17 alleles in other data sets. These features 
increase applicability of the model, while its clinical implications remain to be ascertained. 
 
Our findings are in line with published data assuming a two-compartment model for DM (1, 
35) and one-compartment models for DO.(1) The absorption rate constant (h-1) estimate is 
about 0.25, which lies between previously reported values of 2.6 h-1 and 0.1 h-1.(1, 36) The 
lag time was estimated to be 0.31 h, which also lies between previously reported values 0.8 h 
and 0.087 h.(1, 35) The model estimates for the apparent central and peripheral volumes of 
distribution of DM in this study are smaller at 648 L and 1560 L compared with the 
previously reported values of 961 L and 1951 L.(1) The volume of distribution of DO with 
419 L is smaller than the reported value of 650 L (37) and 3776 L (1), but higher than 109 L 
reported by others. (38) Urine pH plays a significant role as a covariate and explains part of 
the variability seen in DM metabolic ratios. This is in agreement with a previous study 
describing an approximate 20-fold variation in the urinary metabolic ratio due to urinary 
pH.(39) Taken together, these comparisons suggest that our model is valid.  
 
The goodness-of-fit plots (Figure 2) show a possible overestimation of some DM and DO 
concentrations in plasma/urine, both due to model misspecification which is a semi-
mechanistic rather than a fully mechanistic model. This may be explained by the existence of 
other sources of variability that were not taken into account in the final model. Possible 
sources could be the interindividual variability in CYP3A activity, incomplete description of 
the first pass metabolism such as the formation of methoxymorphinan from DM, the lack of 
modeling the metabolic fate of DO, the possible contribution of glucuronidation, and inter-
study variability and lastly, the possibility that further sequence variations were present in 
addition to those covered in the genotype analysis. The interaction between the final model 
and the study design can be seen from the simulated predictive check plots. Generally 
inadequately fitted concentrations form only a negligible fraction of the whole data set.  
 
 10
In conclusion, the final population model adequately described DM pharmacokinetics in 
healthy Caucasian men. The results confirmed that individual CYP2D6 genotype and to a 
lesser degree urine pH contribute to the variability in pharmacokinetic profiles of DM. The 
estimated quantitative differences in the metabolic capacity attributable to copies of 
individual CYP2D6 genes including *1, *2 and *41 suggest that existing scoring systems to 
predict CYP2D6 activity from CYP2D6 genotype need to be refined. To which extent the 
observed activity differences between functional alleles for DM as a substrate are the same for 
other substrates remains to be assessed. (40) 
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Methods 
Study design 
Data derived from 36 healthy Caucasian male volunteers who participated in 3 cocktail 
interaction studies were used for this evaluation; n=15 from study A, n=10 from study B, and 
n=11 from study C.(41, 42) The data evaluated in this study were taken from the respective 
reference period where each subject received a single oral dose of 30 mg DM hydrobromide 
(one capsule of Hustenstiller-ratiopharm, Ratiopharm, Ulm, Germany). Subjects eligible for 
inclusion in the analysis were carriers of one, two or a combination of the following allelic 
variants: CYP2D6*1, *1xN, *2, *2xN, *3, *4, *4xN, *6, *41 or *41xN. Details of 
demographic data of the 36 subjects are shown in Table 1. 
 
Blood samples were collected for quantification of DM and DO as follows: study A 
immediately before administration and 0.17, 0.5, 0.75, 1.0, 1.33, 2.0, 3.15, 4.25, 5.25, 6.0, 8.0, 
10.0, 11.95, 14.0, 24.0 h after dosing; study B immediately before administration and 0.17, 
0.33, 0.50, 1.0, 1.33, 1.67, 2.0, 2.5, 3.25, 3.95, 4.5, 5.25, 7.00, 10.00, 12.0, 16.0, 24.0 h after 
dosing; study C immediately before administration and 0.17, 0.33, 0.50, 0.75, 1.00, 1.33, 
1.67, 2.0, 2.5, 3.25, 3.95, 4.13, 4.25, 4.5, 4.75, 5.0, 5.5, 6.5, 8.0, 10.0, 12.0 h after dosing. 
To determine the urinary metabolic ratio of DM to DO, urine samples were collected 
periodically and their volumes and pH values measured of each collection period. Urine 
sampling schedules were: study A immediately before administration and 0-2, 2-4, 4-6, 6-8, 
8-12, 12-16 und 16-24 h after dosing; study B immediately before administration and, 0-6 und 
6-12 h after dosing; study C immediately before administration and, 0-2, 2-4, 4-6, 6-8, 8-12 h 
after dosing.  
 
Quantification of DM and DO  
Plasma and urine samples were analyzed according to a previously published validated LC-
MS/MS method.(43) Urine samples were treated with β-glucuronidase for cleavage of the DO 
glucuronides before measurement. The lower limits of quantification were 0.103ng/mL for 
DM and 0.101ng/mL for DO. Precision ranged from 3.2 to 7.8% for DM, and from 4.7 to 
9.2% for DO, while accuracy was 101.8–102.9%, and 97.4–99.5% for DM and DO, 
respectively. 
 
Genotyping  
Genotyping was performed essentially as described earlier in detail.(8) Briefly, a 6.6 kb long 
CYP2D6-specific PCR product was generated and subsequently used as a template to 
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determine the presence of allele-identifying SNPs. Gene duplications and the CYP2D6*5 gene 
deletion were also determined by long-range PCR (44)  
 
Population pharmacokinetic modelling  
All plasma and urine-derived data points for DM and DO were analysed simultaneously using 
the nonlinear mixed-effect software in NONMEM version VI (Globomax, LLC, Hanover, 
MD, USA). The analysis was performed using the first-order conditional estimation method 
with interactions (FOCE INTER). Models were specified in set of differential equations using 
the ADVAN6 subroutine and were parameterized for disposition kinetics using apparent 
clearance and volume of distribution terms. 
 
The activity of the non-functional CYP2D6*4, *3 and *6, or null enzyme variants was set to 
zero as these alleles carry inactivating sequence variations 
(http://www.cypalleles.ki.se/cyp2d6.htm). Clearance of DM in individuals with 
CYP2D6*null/*null genotypes was assumed to reflect non-CYP2D6-mediated clearance. 
Hence, the study evaluated the activity of alleles containing CYP2D6*1, *2 and *41 gene 
copies, which have been recognized as true variants influencing DM metabolism activity in 
vivo.(17, 32) In addition to CYP2D6 polymorphisms, age, urine pH, and body weight were 
considered as covariates during model building. An allometric model was tested for weight, 
while exponential and combined models were tested to centre the age effect to the mean or the 
median age values.(45) Different relationships were tested to explore the effect of urine pH on 
renal clearances of DM and DO. Covariates were included in the model in a forward stepwise 
manner and backwards removed starting with the covariate that resulted in most reduction in 
the objective function value (OFV). This procedure was repeated until no significant drop was 
obtained in OFV. 
 
As a starting point for the model building, a four-compartment open model was tested to 
describe the entire data set. Each compartment represents each site of measurement (i.e., two 
compartments each [plasma and urine] for DM data and two compartments for DO data). A 
first-order absorption process with and without a lag time was explored. Disposition processes 
for both substances were assumed to follow linear kinetics. For the purpose of the 
semimechanistic model, DM was assumed to be converted entirely to DO. This metabolic 
clearance was described as follows: CLm = CLb  + CLCYP2D6 where CLm is the total apparent 
clearance of DM describing the biotransformation of DM to DO, CLb  is the basic value for 
DM metabolic clearance that is not subject to CYP2D6 activity, CLCYP2D6 is the metabolic 
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clearance due to CYP2D6 activity. CLCYP2D6=n*1 * CL*1 + n*2 * CL*2 + n*41 * CL*41, where 
n*x and CL*x, are the number of gene copies observed and metabolic clearance values 
attributable to the respective gene. This model was selected as a basic structural model for 
further model building activities.  
 
An exponential interindividual variability model was included for all model parameters 
forward and backward step by step interchangeably. Four residual-error models were added, 
one for each data type (i.e., a separate residual-error model for plasma parent data, another for 
plasma metabolite data etc.). Each residual error model was built up using an additive model, 
a proportional model, or a combination of both. 
 
Model derivation and justification was guided by (i) the difference in the objective function 
value (ΔOFV) generated via NONMEM, a ΔOFV of 3.84 (approximate χ2-distribution) for an 
additional parameter was used to determine statistical significance (P < 0.05) of the difference 
between any two models, (ii) visual inspection of goodness-of-fit plots, as well as (iii) 
physiological plausibility and statistical precision of model parameter estimates. The final 
model performance was also justified by simulating plasma and urine concentration time 
profiles for 1000 subjects having the observed CYP2D6 allele combinations and visualized 
using the Active Perl program (Active Perl, version 5.10.0; ActiveState, Vancouver, Canada). 
 
 
 14
Appendix 
The differential equations specifying the model shown in Figure 1 for a generic individual 
are: 
dA1/ dt = − k12 A1 
Cz = k12 A1 + Q1 C2 / (Q1 + CL23) 
dA2 / dt = Q1 Cz − Q1 C2 − Q2 C2 + Q2 C6 – CL24 C2  
dA3 /dt = CL23 Cz − CL30 C3 − CL35 C3  
dA4 / dt = CL24 C2 
dA5 / dt = CL24 C2 
dA6 / dt = Q2 C2 − Q2 C6 
 
The differential equation for the hypothetical enzyme compartment can be written as follows: 
dCz /dt = k12 A1 + Q1 C2 − Q1 Cz − CL23 Cz 
where Cz is the concentration in the metabolizing compartment. The model assumes rapid 
equilibrium between this compartment and the DM central compartment. 
0 = k12 A1 + Q1 C2 − (Q1 + CL23) Cz 
This equation can be rearranged to get the following expression for Cz 
Cz = k12 A1 + Q1 C2 / (Q1 + CL23) 
 
The differential expression for DM in the central compartment (A2) is: 
dA2 / dt = Q1 Cz − Q1 C2 − Q2 C2 + Q2 C6 – CL24 C2  
After substituting Cz 
dA2 / dt = Q1 (k12 A1 + Q1 C2/( Q1 + CL23)) − Q1 C2 − Q2 C2 + Q2 C6 – CL24 C2 
 
Similarly for the DO plasma compartment: 
dA3 /dt = CL23 Cz − CL30 C3 − CL35 C3 
After substituting Cz: 
dA3 / dt = CL23 ((k12 A1 + Q1 C2)/( Q1 + CL23)) − CL30 C3 − CL35 C3 
 
where Ai and Ci denote the amount and concentration of the species associated with the ith 
compartment in Figure 1. 
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Figure Legends 
 
Figure 1 Blueprint of the final semi-mechanistic population model of dextromethorphan 
(DM) and dextrorphan (DO) in plasma and urine after administration of single oral doses of 
30 mg DM hydrobromide. The absorption phase is described with a rate constant (ka) and lag 
time (tlag). Cp and Cu are plasma and urine concentration of DM or DO in the corresponding 
compartments. Cz is the concentration of DM in the hypothetical metabolizing enzyme 
compartment, which is in rapid equilibration with that in plasma (Cp). Q1 is the 
intercompartmental clearance between the central compartment of DM and the metabolizing 
enzyme compartment. CL23 is the apparent systemic metabolic clearance of DM to DO, which 
is the sum of the basic (CLb) and CYP2D6-mediated (CLCYP2D6) components. Q2 is the 
intercompartmental clearance between central and peripheral compartments of DM, CL24 is 
the renal clearance of DM under the influence of urine pH (UpH), CL35 represents DO renal 
clearance, and CL30 is the clearance of DO to other species. 
 
Figure 2 Goodness-of-fit plots for the final model; a Goodness-of-fit plots for plasma 
concentrations of dextromethorphan (left) and dextrorphan (right); b Goodness-of-fit plots for 
amounts excreted in urine of dextromethorphan (left) and dextrorphan (right). 
 
Figure 3 Visual predictive check plots showing adequacy of the developed model to describe 
the actual data (filled black circles=dextromethorphan data, unfilled circles= dextrorphan) as 
they are almost equally dispersed on the both side of simulated median (50th percentile). 
Plasma observations are shown on the upper panel. 
 
Figure 4 Simulated typical time courses in plasma (upper panel) and urine (lower panel) for 
individuals with different genotypes.
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Tables 
 
Table 1 Demographic data given as mean ± standard deviation (range).  
Values 
Characteristics 
Study A Study B Study C Total 
Number of subjects 
used in the evaluation 
15 10 11 36 
Age (years) 28.5 ± 4.70 
(23 - 38) 
29.6  ±  6.5 
(22 – 43) 
30.5  ± 9.6 
(18 - 48) 
29.4 ± 6.85 
(18 – 49) 
Body weight (kg) 78.1 ± 10.1 
(65– 101.1) 
79.5 ± 9.2 
(66.3 – 92) 
71.7 ± 5.3 
(82 – 60) 
76.5 ± 9.01 
(60 – 101) 
Height (cm) 182.3 ± 7.0 
(171-195) 
180.1 ± 6.4 
(173 – 194) 
180.6 ± 5.8 
(171 – 190) 
181.3 ± 6.38 
(171– 195) 
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Table 2 Genotypes of individuals from the three clinical studies used in this evaluation.  
CYP2D6 
genotype Study A Study B Study C Total 
*1/*1 2  3  1  6 
*1/*2 2  0  2  4 
*1/*4 6  1  0  7 
*1/*41 1  3  1  5 
*4/*4 1  0  0  1 
*2/*4 1  0  3  4 
*2/*41 0  0  1  1 
*4/*41 0  1  0  1 
*1x2/*2 1  0  0  1 
*1/*1x2 0  1  0  1 
*2/*2x2 1  0  0  1 
*2x2/*3 0  1  0  1 
*2/*2 0  0  2  2 
*2/*4x2 0  0  1  1 
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Table 3 Pharmacokinetic parameter estimates for the population  
Model parameter§ Point estimate 95% CI 
Absorption rate constant, ka  (h-1)  0.25 0.23 – 0.27 
Lag time (h) 0.31 0.30 – 0.32 
Apparent volume of distribution of DM in central 
compartment, Vc,,dex  (l) 
648 493 - 803 
Intercompartmental clearance Q1 (l/h) 560 295 - 825 
Apparent volume of distribution of DM in peripheral 
compartment  Vp, dex  (l) 
1560 1092 - 2028 
Intercompartmental clearance, Q2  (l/h) 173 129 - 217 
Apparent renal clearance of DM, CL24 (l/h) 6.52 4.84 – 8.20 
Urine pH effect on DM renal clearance in a man with a 
standard pH value of 5.7 
3.93 2.74 – 5.12 
basic        (l/h) 10.1 6.38 – 13.82 
CYP2D6*1    (l/h, per gene copy) 5010 3579 – 6441 
CYP2D6*2    (l/h, per gene copy) 2020 624 - 3416 
Components 
of apparent 
metabolic 
clearance 
CL23 
CYP2D6*41  (l/h, per gene copy) 85.0 63.8 – 106.2 
Apparent volume of distribution of DO Vm, dor (l) 419 237 - 601 
Age effect  on  Vm, dor (%change/ year)** 0.042 0.016 – 0.068 
Apparent renal clearance of  DO CL35 (l/h) 45.5 34.1 – 56.9 
Apparent clearance of DO to other species  CL30 (l/h) 1260 1061 - 1460 
B
as
ic
 P
ha
rm
ac
ok
in
et
ic
 P
ar
am
et
er
s 
Age effect  on  CL30  (%change/ year)** 0.029 0.003 – 0.055 
BSV_ka (%CV) 20.1 1.3* 
BSV_CL24 (%CV) 69.5 12.5* 
BSV_ CL23 (%CV) 73.8 13.6* 
BSV_CL35 (%CV) 73.8 10.6* 
B
et
w
ee
n 
su
bj
ec
ts
 
va
ri
ab
ili
ty
 (B
SV
) 
BSV_CL30 (%CV) 44.3 5.18* 
Proportional error (%CV) 30.6 1.61* 
DM 
Additive error (μg/L) 0.004 0.122* 
Proportional error (%CV) 32.6 1.06* Pl
as
m
a 
DO 
Additive error (μg/L) 0.006 0.18* 
DM Proportional error (%CV) 56.2 3.82* 
R
es
id
ua
l v
ar
ia
bi
lit
y 
 
U
rin
e 
DO Proportional error (%CV) 44.8 2.95* 
§see Fig. 1 for individual parameters; *= percentage of relative standard error 
** centered around 27 years 
